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Growth hormone promotes glomerular lipid accumulation in
bGH mice.
Background. Bovine growth hormone (bGH) transgenic
mice develop progressive glomerulosclerosis and exhibit abnor-
malities in hepatic lipid metabolism. We have previously shown
that growth hormone up-regulates the low-density lipoprotein
(LDL) receptor and 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGR) in mouse mesangial cells. However, a role
of lipid abnormalities in bGH kidney disease has not yet been
demonstrated.
Methods. Groups of bGH mice (5 and 11 months old) present-
ing with, respectively, moderate and severe degrees of glomeru-
losclerosis were compared to age-matched controls. Neutral
lipid content in kidney cortex was determined by oil red-O stain-
ing, serum cholesterol, and triglycerides by enzymatic assays,
relative mRNA expression of LDL receptors, HMGR, and scav-
enger receptor by real-time reverse transcription-polymerase
chain reaction (RT-PCR), and HMGR protein expression by
immunoblotting. Two younger (5 and 12 weeks old) groups of
mice were used to study scavenger receptor expression at earlier
time points.
Results. Serum cholesterol was significantly increased in bGH
mice at 5 months, but triglycerides were lower than control
levels at both 5 and 11 months. Renal cortex HMGR expres-
sion was elevated at the mRNA but not at the protein level in
the 11-month-old bGH group compared to controls. However,
glomerular neutral lipid staining and scavenger receptor mRNA
expression were markedly increased in all bGH mice, including
those at 5 weeks of age compared to respective controls.
Conclusion. The bGH mouse exhibits an increased mesangial
lipid content and elevated scavenger receptor mRNA expres-
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sion as early as at 5 weeks of age, suggesting that an increased
kidney uptake of oxidized LDL could play a role in the devel-
opment of glomerulosclerosis in this mouse model.
Glomerulosclerosis is characterized by glomerular le-
sions, which include partial or total replacement of the
glomerular tuft by a fibrous scar, resulting in progressive
loss of renal function [1]. It constitutes a common fea-
ture of most chronic kidney diseases, including diabetic
nephropathy. Of the several animal models of glomeru-
losclerosis in widespread use, the bovine growth hormone
(bGH) transgenic mouse is of particular interest as it
develops glomerular lesions that bear a marked resem-
blance to those present in human diabetic nephropathy
[2]. Because of the progressive nature of the disease, the
bGH mouse has become a model to study the pathophysi-
ology of glomerulosclerosis. Furthermore, the clinical ob-
servation that in acromegaly, abnormally high circulating
levels of growth hormone are accompanied by an increase
in albuminuria and urinary excretion of glycosaminogly-
cans, early markers of glomerular injury, strongly sup-
ports the involvement of elevated growth hormone in
the pathogenesis of glomerular disease [3]. The role of
growth hormone in the development of glomerulosclero-
sis has also been demonstrated in dwarf models of dia-
betes and subtotal nephrectomy, where growth hormone
deficiency was shown to markedly attenuate the severity
of glomerular injury [4–7].
It has been reported recently that excess growth hor-
mone in the bGH transgenic mouse leads to hyperc-
holesterolemia and several abnormalities in hepatic lipid
metabolism [8, 9], but the involvement of lipids in the de-
velopment of glomerulosclerosis has not yet been stud-
ied in this model. Histopathologic similarities between
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glomerulosclerosis and atherosclerosis suggest that sub-
sequent to the initial hormonal, metabolic or hemo-
dynamic insult, the development of glomerulosclerosis
follows a course analogous to that of lipid-induced vas-
cular disease [10–13]. As in atherosclerosis, an increased
presence of macrophages in the glomerular area, fol-
lowed by increased glomerular lipid deposition, mesan-
gial cell proliferation and extracellular matrix expansion
have been demonstrated in several types of experimen-
tal and clinical nephropathies [10, 11, 14]. Furthermore,
the demonstration that glomerular low-density lipopro-
tein (LDL) deposits induce both mesangial cell prolifer-
ation [15–18] and extracellular matrix accumulation [19]
supports the idea that lipid deposition may underlie the
development of glomerulosclerosis.
In the presence of hyperlipidemia, an increased scav-
enger receptor–mediated uptake of oxidized LDL by
glomerular macrophages leads to the development of
glomerular foam cells [12, 20]. In addition, cultured hu-
man mesangial cells have been shown to accumulate
lipids in the presence of high concentrations of LDL
through both class A scavenger receptor [21, 22] and LDL
receptor [23–25].
Despite the recognized association between hyperlipi-
demia and both atherosclerosis and glomerulosclerosis,
there is evidence that mesangial lipid accumulation in
glomerular diseases may occur independently of serum
lipid levels, related instead to the renal up-regulation of
LDL receptor and scavenger receptor [26, 27].
We have previously shown that growth hormone in-
creased LDL receptor and 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGR) transcript levels in
mouse mesangial cells cultured in the absence of lipopro-
tein [28]. These results suggest a model in which growth
hormone mediates the development of glomerulosclero-
sis in part by a direct mesangial up-regulation of genes
involved in lipid metabolism. In the present study, we
extended our in vitro studies to an in vivo model of
glomerulosclerosis (bGH transgenic mouse) to examine
the influence of growth hormone on the renal expres-
sion of genes involved in the regulation of lipid synthe-
sis and uptake during the course of glomerulosclerosis.
We first measured the renal expression of LDL recep-
tor, HMGR, and scavenger receptor at both moderate
and severe stages of chronic kidney disease, respectively,
5- and 11-month-old animals. In addition, the levels of
serum creatinine, cholesterol, and triglycerides, as well as
accumulation of intraglomerular lipid were compared be-
tween bGH and age-matched control animals. In a second
study, four additional groups of animals (bGH and non-
transgenic at 5 and 12 weeks of age, five animals/group)
were included specifically to ascertain the earliest occur-
rence of a difference in glomerular lipid accumulation
and scavenger receptor expression between the bGH and
nontransgenic groups.
METHODS
Animals
bGH transgenic mice and nontransgenic littermates
were provided by Dr. John J. Kopchick (Edison Biotech-
nology Institute, Ohio University, Athens, OH, USA).
The animals were housed one per cage, with free access to
water and mouse chow (rat/mouse standard diet) (Harlan
Teklad, Madison, WI, USA) in alternating 12-hour peri-
ods of light and dark. A total of 28 male mice were divided
into age group I (5 months old) (nine nontransgenic and
10 bGH) and age group II (11 months old) (five non-
transgenic and four bGH), representing moderate and
severe stages of glomerulosclerosis, respectively [29]. In
a second study, four groups of animals were euthanized
at a younger age (bGH and nontransgenic mice, 5 and
12 weeks of age, five animals/group). All animal proce-
dures were carried out in accordance with the regulations
of the USUHS Laboratory Review Board and with the
Guide for the Care and Use of Laboratory Animal, Insti-
tute of Laboratory Animal Resources, National Research
Council, 1996.
Animals were weighed and euthanized by decapitation
following sedation with intraperitoneal injection (12 lL/g
body weight) of Avertin (25 g tribromoethanol/12.5 mL
tertiary amyl-alcohol) at 1/40 dilution in saline [30]. All
mice were euthanized in the morning to avoid the ef-
fects of diurnal variation. Total blood was collected and
allowed to clot, followed by separation of serum, which
was kept at −80◦C until analysis. Kidneys were quickly
excised and weighed. Samples of kidney cortex were col-
lected for RNA extraction and for preparation of his-
tology sections (frozen and paraffin-embedded). In the
second study, prior to euthanasia the 5-week-old non-
transgenic and bGH animals were grouped in separate
metabolic cages (five animals per group) for a period of
3 hours in 3 consecutive days for urine collection and
further assessment of proteinuria.
Light microscopy
A coronal section of the right kidney was fixed in
10% buffered formalin and embedded in glycol methy-
lacrylate. Sections (3 lm) were stained with periodic
acid-Schiff (PAS) and examined by an independent
investigator blinded to the study to determine the de-
gree of glomerular injury, indicated by a glomeruloscle-
rosis score. The scoring system was based on the modified
Banff classification [31] using data collected from the
analysis of 20 glomeruli/mouse that were randomly
scanned proceeding from the outer cortex to the jux-
taglomerular zone in a serpentine fashion. First, each
glomerulus was graded (0 to 4) according to the per-
centage of sclerosis/glomerular area, grade 0 being given
to glomeruli with no sclerosis and grade 4 to obsoles-
cent glomeruli. Subsequently, a final score was attributed
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to each animal according to the percentage of sclerotic
glomeruli previously graded, score 0 being given to ani-
mals with less than 10% grade 1 glomeruli and score 4 to
animals with >75% grade 3 glomeruli and ≥10% grade
4 glomeruli.
Neutral lipid staining
Fresh kidney tissue was immediately frozen in
22-oxacalcitriol (OCT) compound (Miles Scientific,
Naperville, IL, USA), and cryostat sections of 14 lm were
fixed in 40% formalin for 5 minutes. A fresh working so-
lution of oil red-O was prepared by dilution of the oil
red-O stock solution (5 g/L in 98% isopropanol) in dis-
tilled H2O in a ratio of 3:2. The working solution was
allowed to stand for 10 minutes, after mixing and was fil-
tered in a 0.45 l filter. Subsequently, sections were stained
in oil red-O for 10 minutes, washed in tap water and coun-
terstained with Harris hematoxylin solution followed by
dipping in ammonia water (28% ammonium hydrox-
ide). The slides were allowed to dry and were mounted
with Vectashield mounting medium (Vector Laborato-
ries, Burlingame, CA, USA).
Light microscopy of oil red-O–stained sections of kid-
ney cortex was performed and the number of glomeruli
with positive neutral lipid staining was determined to cal-
culate the percentage of oil red-O–positive glomeruli per
total number of glomeruli for each section. The average
percentage of neutral lipid-positive glomeruli was com-
pared between bGH and respective age-matched control
groups.
Biochemical analyses
Cholesterol and triglyceride serum concentrations
were determined using the Infinity Kit from Sigma
Diagnostic (St. Louis, MO, USA), following the manu-
facturer’s protocol. Serum creatinine was measured by
a colorimetric assay based on the Jaffe´ reaction using
a commercial kit (Sigma Diagnostics). Proteinuria was
measured in urine samples collected from the 5 week-old
bGH and nontransgenic mice by reagent strips (Multistix
10SG) (Bayer Co., Elkhart, IN, USA).
RNA extraction and real time reverse
transcription-polymerase chain reaction (RT-PCR)
Samples of renal cortex were homogenized and total
RNA was extracted using the Rneasy Mini Kit (Qiagen,
Valencia, CA, USA) following the manufacturer’s
protocol. This procedure included a DNAse step to elim-
inate genomic DNA contamination. Total RNA con-
centration was determined by absorbance at 260 nm.
Aliquots of 100 ng of each sample in duplicate were
employed to determine a relative quantification of tar-
get transcript using real-time RT-PCR with the Taq-
Man One-Step RT-PCR Master Mix Reagents (Applied
Biosystems, Foster City, CA, USA) and the ABI 7700 Se-
quence Detector System (Applied Biosystems). The fi-
nal concentrations of primers and probes in the reaction
were optimized for multiplex real time RT-PCR as fol-
lows: HMGR forward and reverse primers 150 nmol/L,
probe 150 nmol/L; LDL receptor forward and reverse
primers 300 nmol/L, probe 200 nmol/L; scavenger re-
ceptor forward and reverse primers 300 nmol/L, probe
250 nmol/L; and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) forward and reverse primers 40 nmol/L,
probe 200 nmol/L. All reactions were carried out at 48◦C
for 30 minutes (RT step), followed by one cycle of 95◦C
for 10 minutes and 40 cycles of 95◦C for 15 seconds and
60◦C for 1 minute.
Each target transcript was coamplified with GAPDH in
a multiplex RT-PCR assay. Normalization was calculated
by the difference between target and GAPDH CT levels
(CT). Subsequently, a quantification of target mRNA
in bGH mice relative to control animals was calculated
by the difference between CT values (CT) and ex-
pressed as fold change using the formula 2−CT (User
Bulletin # 2) (PE Applied Biosystems).
Primers and TaqMan probes
Primers and TaqMan probes specific for mouse
HMGR, LDL receptor, scavenger receptor (recognizing
class A types I and II) were designed using Primer Ex-
press software (Applied Biosystems). Specificity of tran-
script amplification was verified using a nucleotide Basic
Local Alignment Search Tool (BLAST) (National Cen-
ter for Biotechnology Information, NIH, Bethesda, MD,
USA). Probes for target genes were labeled with a re-
porter dye (FAM) at the 5′ end and a quencher (TAM)
at the 3′ end, and were synthesized at the Core Labora-
tory of the Center for Biologics Evaluation and Research
(CBER) (Food and Drug Administration, Bethesda, MD,
USA). A set of primers and TaqMan probe for the
housekeeping gene GAPDH was obtained from PE Ap-
plied Biosystems. The GAPDH probe was labeled with
the fluorophore VIC at the 5′ end and TAM at the 3′ end.
The sequences of primers and probes for HMGR, LDL
receptor and scavenger receptor are shown in Table 1.
Western blot
Total protein was extracted from kidney cortex samples
using glass homogenizers with ice-cold buffer containing
50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 0.5%
sodium deoxycholate, 1% NP-40, 0.1% sodium dodecyl
sulfate (SDS), 5 mmol/L ethylenediaminetetraacetic acid
(EDTA), to which was added dithiothreitol (DTT) to a
final concentration of 1 mmol/L and one pill of protease
inhibitors (Roche Pharmaceuticals, Nutley, NJ, USA) per
10 mL of buffer. Tissue homogenate was centrifuged at
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Table 1. DNA sequence of primers and probes used in real-time reverse transcription-polymerase chain reaction (RT-PCR)
Forward primer Reverse primer Probe
HMGR tctggcagtcagtgggaactatt cctcgtccttcgatccaattt caccgacaagaagcctgctgcca
LDL receptor gctccataggctatctgctcttca ctgcggtccagggtcatc caaccgccacgaggtccgga
Scavenger receptor catgaacgagaggatgctgact aggaagggatgctgtcattga cagttcagaatccgtgaaatttgacgcac
HMGR is 3-hydroxy-3-methylglutaryl coenzyme A reductase; LDL is low-density lipoprotein. Sequences are oriented in the 5′-3′ direction. Probes were designed
according to the TaqManTM technology, labeled with the fluorophores FAM and TAM, respectively at the 5′ and 3′ ends.
Table 2. Kidney weight, glomerulosclerosis (GS) scores and serum lipids of bovine growth hormone (bGH) compared to control mice at 5 and
11 months of age
Serum concentration
Body weight g Kidney weight g Kidney weight/body weight mg/g GS score mean (min-max) Cholesterol Triglycerides
5 months
bGH 50.8 ± 1.1a 0.64 ± 0.09a 12.7 ± 2.0 3.3 (2.0-4.0)a 181.2 ± 9.0a 85.6 ± 8.0
Nontransgenic 33.5 ± 1.1 0.31 ± 0.06 9.1 ± 1.8 0.3 (0.0-1.0) 135.8 ± 6.6 120.2 ± 13.8
11 months
bGH 51.8 ± 1.1a 0.56 ± 0.05a 10.9 ± 1.0a 4.0 (4.0-4.0)a 114.3 ± 8.6 50.6 ± 7.7b
Nontransgenic 35.6 ± 1.5 0.25 ± 0.02 7.4 ± 0.7 0.9 (0.0-1.0) 136.6 ± 5.1 122.4 ± 17.5
Results in mean ± SEM. Level of significance P < 0.05.
aValue significantly higher compared to age-matched nontransgenic animals.
bValue significantly lower compared to age-matched nontransgenic animals.
10,000 × g at 4◦C for 20 minutes. The supernatant was
collected and protein concentration was determined us-
ing the Bio-Rad Protein Assay Dye Reagent (Bio-Rad
Laboratories, Hercules, CA, USA).
Aliquots of 30 lg of protein were added to Bio-Rad
SDS sample buffer (Bio-Rad Laboratories), 1× Nu-
PAGE Reducing Agent (Invitrogen Corp., Carlsbad, CA,
USA) in a total volume of 20 lL and heated at 70◦C for
10 minutes. Samples were loaded on 4% to 12% Nu-
PAGE Novex Bis-Tris precast gels (Invitrogen Corp.)
with NuPAGE 3-[N-morpholino] protein sulfonic acid
(MOPS) SDS Running Buffer (Invitrogen Corp.) con-
taining 0.25% NuPAGE Antioxidant (Invitrogen Corp.)
and were subjected to electrophoresis at 125 V. Sub-
sequently, proteins were transferred from the gel to a
polyvinylidine difluoride (PVDF) membrane with Nu-
PAGE Transfer Buffer (Invitrogen Corp.) containing
20% methanol and 0.1% NuPAGE Antioxidant (Invit-
rogen Corp.).
The blotted membranes were incubated in blocking so-
lution [5% fat-free milk and 0.1% Tween-20 in phosphate
buffered saline (PBS)] for 1 hour at room temperature,
followed by incubation with rabbit antimouse HMGR
antibody (Upstate USA, Charlottesville, VA, USA) di-
luted 1:500 in blocking solution for 2 hours at 4◦C. Sub-
sequently, the blotted membrane was washed three times
in PBS with 0.1% Tween-20 for 10 minutes at room
temperature, followed by incubation with goat antirab-
bit horseradish peroxidase (HRP)–conjugated antibody
(Pierce Chemical Co., Rockford, IL, USA) diluted 1:5000
in blocking solution for 90 minutes at room temperature.
After three washes of 10 minutes each, the membrane
was immersed in the SuperSignal West Pico chemilumi-
nescent substrate (Pierce Chemical Co.) with constant ag-
itation for 5 minutes and exposed to a high-performance
chemiluminescence film (Hyperfilm ECL) (Amersham
Biosciences, Piscataway, NJ, USA) for 5 to 10 seconds.
The film was developed and the image was scanned to
a computer for densitometric analysis using NIH Image
software (National Institutes of Health, Bethesda, MD,
USA).
Statistical analyses
Glomerulosclerosis scores were analyzed by a non-
parametric test (Kruskal-Wallis) followed by Dunn’s post
test. Other parameters were compared by one-way anal-
ysis of variance (ANOVA) followed by Bonferroni test
using InStat software (Graph-Pad, San Diego, CA, USA).
For real-time RT-PCR assays, significance was deter-
mined by a comparison of the CT values calculated for
each experimental group rather than from the formula-
derived (2−CT) fold change from control. The level of
significance accepted was P < 0.05.
RESULTS
The influence of excess growth hormone on kidney
morphology in the bGH transgenic mouse model at 5
and 11 months is illustrated in Table 2 and Figure 1A. All
bGH transgenic mice exhibited a significant increase in
body and kidney weight compared to age-matched non-
transgenic controls. The kidney to body weight ratio was
approximately 1.4-fold higher in bGH compared to non-
transgenic mice in both age groups, but a statistically sig-
nificant difference was achieved only in the 11-month-old
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Fig. 1. Photomicrograph of representative glomeruli from bovine growth hormone (bGH) and nontransgenic (NT) mice at 5 and 11 months of age
(A) and at 5 weeks of age (B), stained with periodic acid-Schiff (PAS) reagent and with oil red-O (ORO). (A) Note the PAS-stained extracellular
matrix accumulated within bGH glomeruli with collapsed capillary loops at 5 months and particularly at 11 months of age. In contrast, glomeruli
of age-matched nontransgenic animals exhibit open capillary loops and no extracellular matrix accumulation in the mesangium. Neutral lipid
accumulation indicated by oil red-O–positive staining (arrows) was present in a significantly higher percentage of glomeruli in bGH compared to
nontransgenic mice at both 5 and 11 months. (B) At 5 weeks of age, there was no evidence of PAS-stained extracellular matrix accumulation at
light microscopy examination in bGH compared to control mice. However, the percentage of glomeruli showing positive staining for neutral lipid
(arrow) was significantly increased in bGH compared to age-matched controls (magnification 40×).
group. Glomeruli from both groups were scored as de-
scribed in the Methods section, and bGH mice at both
5 and 11 months old were found to have significantly el-
evated glomerulosclerosis scores compared to their age-
matched controls (Table 2). Serum creatinine levels were
not significantly different among groups (0.51 ± 0.07 and
0.40 ± 0.03, respectively, for nontransgenic and bGH
at 5 months; 0.36 ± 0.03 and 0.35 ± 0.05, respectively,
for nontransgenic and bGH at 11 months) (values are
mean ± SEM).
The influence of the bGH genotype on the serum lipid
profile is also illustrated in Table 2. Serum cholesterol
levels were significantly higher (by approximately 25%)
in bGH mice compared to their control counterparts at
5 months of age, but no difference in cholesterol levels
between bGH and nontransgenic mice was detected at
11 months. Furthermore, serum triglycerides exhibited a
trend to decrease in the bGH group at 5 months and by
11 months were significantly reduced in bGH compared
to age-matched nontransgenic mice.
Despite the finding of normal cholesterol and low
triglyceride serum levels in bGH mice at 11 months, pos-
itive oil red-O staining, a reflection of neutral lipid con-
tent, was nevertheless markedly increased in glomeruli
of bGH mice compared to controls in both the 5-
and 11-month-old age groups. A total of 20 ± 10
glomeruli/section were analyzed, and the percentage of
glomeruli with positive oil red-O staining was signifi-
cantly increased in the bGH group (P < 0.05, ANOVA
followed by Tukey-Kramer test for multiple compar-
isons) (values are mean ± SD) at both 5 months
(46.8 ± 30.1 vs. 0.8 ± 2.4, respectively, for bGH and
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nontransgenic) and 11 months (73.5 ± 18.8 vs. 7.7 ±
11.6, respectively, for bGH and nontransgenic). Repre-
sentative PAS- and oil red-O–stained sections of renal
cortex illustrating the advanced degree of extracellular
matrix accumulation and glomerular neutral lipid depo-
sition in bGH compared to nontransgenic mice at both 5
and 11 months of age are shown in Figure 1A.
Most of the oil red-O staining was associated with
glomeruli rather than with tubular or interstitial areas.
The disparity between oil red-O staining and serum lev-
els of cholesterol at 11 months suggested that the bGH-
related increase in glomerular lipid may be more directly
related to the influence of growth hormone on lipid-
handling pathways than it is to circulating lipid levels. To
examine whether the glomerular neutral lipid deposition
in bGH mice occurred as a consequence of or as a pre-
cursor of the sclerotic process, we studied an additional
group of animals at a very young age (5 weeks), in which
there was no discernible difference between bGH and
nontransgenic in PAS-stained mesangial matrix. Despite
the absence of any noticeable sign of glomerulosclerosis,
the percentage of glomeruli with positive staining for oil
red-O was significantly increased in bGH compared to
age-matched controls (76.2 ± 11.5 vs. 1.0 ± 2.2, respec-
tively, for bGH and nontransgenic) (values are mean ±
SD) at 5 weeks of age. Representative PAS- and oil red-
O–stained sections for nontransgenic and bGH mice at
5 weeks are illustrated in Figure 1B. The absence of ev-
ident glomerular scarring at 5 weeks was supported by
our findings that proteinuria was absent in bGH as was
in nontransgenic mice.
To further assess the role of growth hormone in directly
affecting glomerular lipid, we employed real-time PCR
to measure the growth hormone effect on enzymes and
receptors regulating mesangial cholesterol synthesis and
uptake. Our results showed that HMGR expression in
the 5-month-old bGH mice was not significantly differ-
ent from age-matched controls, but by 11 months tran-
script levels of HMGR were increased by approximately
sixfold in bGH compared to their control counterparts
(Fig. 2A). However, there was no significant difference
in immunoreactive HMGR protein between bGH and
control animals at either 5 or 11 months as measured by
densitometric analysis of Western blots (Fig. 2B). Fur-
thermore, the mRNA expression of LDL receptor did
not show a significant difference between bGH and non-
transgenic at either time point (Fig. 3A), suggesting that
the activity of the HMGR and LDL receptor in the kid-
ney cortex was not significantly affected by the increased
serum cholesterol in the 5-month-old bGH mice. In con-
trast, scavenger receptor transcript levels were markedly
elevated by eightfold in bGH mice at 5 months of age
and this growth hormone–related increase was sustained
(fourfold above control) through the course of the kid-
ney disease up to 11 months of age compared with age-
matched controls (Fig. 3B).
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Fig. 2. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase (HMGR) mRNA and protein expression in bovine growth hor-
mone (bGH) and nontransgenic (NT) mice at 5 and 11 months.
(A) Transcript levels measured by real-time reverse transcription-
polymerase chain reaction (RT-PCR) are significantly increased in bGH
mice at 11 months, but not at 5 months compared to respective age-
matched controls. Bars represent fold change of bGH values over age-
matched nontransgenic (calculated by the formula 2−CT) and are
mean ± SEM of three independent experiments. Significant differences
between groups were determined by analysis of variance (ANOVA) fol-
lowed by Bonferroni multiple comparisons on CT values. (B) Repre-
sentative Western blot showing immunoreactive HMGR (90 kD band)
in protein samples extracted from kidney cortex of bGH and nontrans-
genic mice at 5 and 11 months. A quantitative analysis (graph) shows
no significant difference in immunoreactive HMGR content between
bGH and age-matched nontransgenic mice. Values are mean ± SEM of
two independent experiments. ∗P < 0.05 vs. nontransgenic at 11 months.
Subsequent to the initial study of scavenger recep-
tor expression in 5- and 11-month-old (i.e., 20 and 44
weeks) mice, we extended these experiments to include
bGH mice and age-matched controls at 5 and 12 weeks
(Fig. 4). As shown in context with the 5- and 11-month-old
data (Fig. 4A), scavenger receptor transcript level was al-
ready significantly elevated above its nontransgenic con-
trol as early as at 5 weeks. Figure 4B expresses the data
from Figure 4A normalized to the 5-week-old nontrans-
genic as a control, thereby emphasizing the degree of
increase in scavenger receptor mRNA over the course of
the progressive glomerulosclerosis. Figure 4B also shows
an increased expression level of this receptor in control
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Fig. 3. Relative mRNA expression of low-density lipoprotein (LDL)
receptor (A) and scavenger receptor (B) measured by real-time reverse
transcription-polymerase chain reaction (RT-PCR) in kidney cortex of
bovine growth hormone (bGH) and nontransgenic (NT) mice at 5 and
11 months of age. There were no significant differences in LDL receptor
transcript levels between bGH and age-matched controls at either 5
or 11 months (A). In contrast, scavenger receptor mRNA expression
was markedly elevated in bGH compared to nontransgenic in both age
groups (B). Bars represent fold change of bGH values over age-matched
nontransgenic and are mean ± SEM of three independent experiments.
∗P < 0.05 vs. age-matched controls.
animals at 11 months (44 weeks) compared to the 5-week-
old nontransgenic. Protein expression of scavenger recep-
tor was not assessed in this study because the antibodies
against this receptor commercially available recognize an
epitope that is polymorphic in C57BL/6 mouse strain,
from which the bGH and nontransgenic mice strains are
derived [32].
DISCUSSION
The bGH transgenic mouse typically exhibits an in-
creased body and kidney weight accompanied by devel-
opment of progressive glomerulosclerosis, [29, 33, 34].
In the present study, these characteristics were found at
both 5 and 11 months of age. In addition, a higher rela-
tive kidney weight with severe glomerular lesions (high-
est glomerulosclerosis scores) at 11 months compared to
5-month-old bGH mice was consistent with the progres-
sive nature of the disease [29, 35].
Despite the elevated serum insulin and the remark-
able similarity between the histopathologic characteris-
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Fig. 4. To study the expression of scavenger receptor throughout the
course of glomerulosclerosis, results from earlier time points (5 and
12 weeks) were combined with those of 5 and 11 months (data from
Figure 3B, identified in this figure as 20 and 44 weeks). (A) Bars rep-
resent fold change compared to the respective age-matched control.
(B) Normalization of scavenger receptor mRNA expression to the av-
erage value of control mice at the earliest time point (nontransgenic
5 weeks). Significant differences between groups were determined by
analysis of variance (ANOVA) followed by Bonferroni multiple com-
parisons of CT values. ∗P < 0.05 vs. age-matched nontransgenic (A)
and vs. 5-week-old nontransgenic (B).
tics of the growth hormone–induced glomerular lesion
and that of diabetic nephropathy, serum glucose remains
within a normal range in the bGH mice [8, 29, 35] elimi-
nating a possible contribution of diabetes mellitus in this
model of glomerulosclerosis. Serum lipid levels, however,
are altered in these animals and have been associated
with the elevated concentration of circulating growth
hormone in the bGH transgenic mouse [8, 34]. Our
present findings furthermore show that serum lipid lev-
els vary with age in the bGH mouse. At 5 months, serum
cholesterol was increased compared to age-matched non-
transgenic controls. Similar results were shown by other
investigators in the bGH mouse at 8 months of age
[8]. However, our studies showed that by 11 months,
when these mice exhibit a severe degree of renal dis-
ease, serum cholesterol had fallen to control levels. We
suggest that the temporal variations in serum cholesterol
observed here may reflect the combined effects of growth
hormone excess as well as hemodynamic and metabolic
2026 Machado et al: Growth hormone promotes glomerular lipid accumulation
changes accompanying the progression of chronic kidney
disease.
The role of growth hormone–induced renal disease
on serum lipid is complicated, however, since growth
hormone has a dual effect on lipid metabolism. Admin-
istration of growth hormone to individuals with growth
hormone deficiency is beneficial in correcting the severe
lipid abnormalities observed in this condition [36–38].
Conversely, supraphysiologic levels of growth hormone
(e.g., those occurring in acromegaly) have an opposite
effect leading to hyperlipidemia and increased risk for
cardiovascular disease [39]. Although both excess growth
hormone and chronic kidney disease favor an increase in
serum triglycerides [39, 40], a decrease in triglycerides
accompanied by a low serum concentration of free fatty
acids has been previously reported in the bGH mouse and
is corroborated in the present study [8]. The decrease in
triglycerides has been attributed to a reduction in synthe-
sis as this abnormality was reversed by administration of
a high-fat diet [8].
An increase in serum cholesterol is often seen in the
course of clinical and experimental chronic kidney dis-
eases [41–44] demonstrating that renal disease, espe-
cially when accompanied by proteinuria plays a role in
the pathogenesis of hypercholesterolemia. Conversely,
a prospective large-scale clinical investigation involving
more than 22,000 apparently healthy males has shown
that high circulating cholesterol levels represent a risk
for renal disease, supporting the hypothesis that kidney
damage may be produced by hypercholesterolemia [45].
Indeed, in both experimental and clinical chronic kidney
diseases accompanied by hyperlipidemia, lipid deposits
are often in evidence in the mesangium [46, 47]. In the
present study, mesangial lipid deposition was increased in
bGH mice as early as at 5 weeks of age and was sustained
up to 11 months compared to respective controls, and yet
circulating cholesterol levels were at normal levels in the
11-month-old animals. The lack of a direct correlation be-
tween serum cholesterol level and increased glomerular
lipid deposition in our bGH model led us to investigate in-
trinsic mesangial pathways of lipid synthesis and uptake
to explain the increased glomerular lipid accumulation
with growth hormone excess.
Increased urinary protein excretion per se has also
been associated with direct glomerular damage, in part,
through accumulation of lipoperoxidation end products
in the glomerulus [48] and thus the role of proteinuria in
our present findings is of interest. However, data pre-
viously published [29, 35] by other investigators and
observations from our laboratory (unpublished) have
demonstrated that proteinuria is significantly elevated
only at moderate and severe stages of glomerulosclerosis
in the bGH model. In the present study, there was no dif-
ference in urinary protein content in bGH compared to
control mice at 5 weeks of age and yet, glomerular neutral
lipid staining was positive at this early point, suggesting
that proteinuria does not play a major role in initiating
the elevated glomerular lipid accumulation in the bGH
model.
Lipid deposits in the kidney have been observed in
various types of nephropathies independent of hyperlipi-
demia and have been associated with increased renal ex-
pression of LDL and scavenger receptor, suggesting that
local factors play an important role in glomerular lipid
accumulation [26]. In the transgenic bGH mouse, bovine
growth hormone, in addition to being abnormally high in
the circulation, is ectopically expressed at different lev-
els by several organs, including liver and kidney [33, 34],
where it may exert significant autocrine effects. Studies
performed with 6-month-old bGH mice have shown that
expression of several genes, including receptors and en-
zymes that regulate lipid metabolism, was markedly af-
fected by growth hormone excess in the liver of this mouse
model [9].
Our present findings demonstrate that the regulation
of lipid metabolism is also altered in the kidney of the
bGH mouse and suggest that the high levels of growth
hormone lead to glomerular lipid accumulation in this
animal model. Regarding the source of the glomerular
lipid, cholesterol synthesis, and/or uptake, the present re-
sults do not support an influence of growth hormone on
LDL receptor in the renal cortex of bGH mouse. This re-
sult was surprising in light of our previous observation of
growth hormone–induced up-regulation of LDL recep-
tor in mouse mesangial cells in vitro [28]. This may be
explained by the fact that the earlier result was obtained
with cells cultured in a lipoprotein-deficient medium,
which may not reflect the LDL milieu in the glomeru-
lus in the present in vivo study. As for cholesterol syn-
thesis, although an increased HMGR mRNA expression
was observed in the bGH renal cortex at 11 months of
age, no significant difference was found in HMGR pro-
tein expression in the kidney cortex of bGH compared
to control mice at either 5 or 11 months of age, sug-
gesting that the contribution of cholesterol synthesis to
the glomerular lipid deposition is probably less impor-
tant than other pathways leading to lipid accumulation.
The discrepancy between mRNA and protein expression
may have resulted from posttranscriptional regulation of
HMGR.
In contrast, scavenger receptor transcript levels, which
are not regulated by intracellular lipid feedback mecha-
nisms, were markedly elevated in the bGH mouse (800%
above controls at 5 months). The increase above age-
matched control fell to fourfold at 11 months largely
because of a twofold increase in scavenger receptor ex-
pression in the nontransgenic group. Thus, the high level
of scavenger receptor expression in the bGH renal cortex
was in fact sustained through the course of the disease
up to 11 months of age. The study of younger animals
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demonstrated that scavenger receptor expression was
markedly up-regulated in bGH compared with nontrans-
genic mice as early as at 5 weeks. The findings of an early
occurrence of class A scavenger receptor increase in the
bGH model strongly suggest that scavenger receptor up-
regulation could be a precipitating event in the observed
elevation in glomerular lipid. Apart from the growth hor-
mone influence on scavenger receptor transcript level, the
apparent age-related increase in this transcript in control
mice raises the possibility that this receptor, in addition
to its involvement in experimental models of glomeru-
losclerosis could play a role in the development of chronic
kidney disease in the aging process.
Class A scavenger receptor is macrophage-specific, but
is also expressed in other cell types, including smooth
muscle [49, 50] and rat mesangial cells [21]. It is notewor-
thy that human and mouse mesangial cells lose the abil-
ity to express this receptor when transferred from in vivo
to in vitro conditions [22]. However, it has been shown
that in cultured rat mesangial cells, an increased uptake
of oxidized LDL by scavenger receptor can lead to the
formation of foam cells in vitro [21]. In addition, a body
of evidence has shown that scavenger receptor–mediated
oxizided LDL uptake plays a major role in foam cell for-
mation and lipid accumulation in chronic kidney diseases
[10, 11]. The positive oil red-O staining that we show in
the mesangium of bGH mice therefore could reflect ei-
ther macrophage or mesangial foam cell localization, as
seen in diet-induced hyperlipidemic models of glomeru-
losclerosis [47, 51].
Takemura et al [26], using immunohistochemical tech-
niques, have demonstrated that scavenger receptor was
up-regulated in both glomerular epithelial and mesan-
gial cells in various kidney diseases [26]. Our present
results suggest that this up-regulation of scavenger re-
ceptor in both clinical and experimental glomerular dis-
ease may involve an increased presence of scavenger
receptor transcripts in the mesangium. However, it re-
mains to be defined whether the elevated transcript rep-
resents transcriptional up-regulation of resident cells or
whether it represents an increased influx of cells (mono-
cytes/macrophages) expressing a high level of the recep-
tor. There is to our knowledge no data on the growth
hormone regulation of class A scavenger receptor ex-
pression. Nonetheless, it is of interest that renal cortex
scavenger receptor A in the present study responds op-
positely to growth hormone than does hepatic class B
scavenger receptor in a bGH transgenic mouse model
[9].
CONCLUSION
Our present findings of increased scavenger receptor
expression in the kidney of bGH mice compared with
nontransgenic controls suggest an endocrine and/or au-
tocrine growth hormone effect in the kidney that may
help to explain the mesangial lipid deposition in absence
of hyperlipidemia in the advanced stages of glomeru-
losclerosis. Our results further support the hypothesis
that growth hormone–induced lipid alterations in the kid-
ney contribute to the development of glomerulosclerosis
in the bGH mouse model.
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